Clinical Trial Update: Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluating second-line FOLFOX with or without regorafenib in metastatic colorectal cancer after failure of first-line irinotecan plus fluorop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid) (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Regorafenib (regorafenib)

Snippet

Sponsor: Asan Medical Center | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: WITHDRAWN